New treatment options for elderly myeloma patients: the Italian experience


https://doi.org/10.4081/hmr.v3i3.557
Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
Published: June 12, 2009
Abstract Views: 178
PDF: 252
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Multiple myeloma accounts for approximately 10% of hematologic malignancies, the frequency is constantly increasing due to aging of the general population.1,2 Recently, novel agents, such as thalidomide, bortezomib and lenalidomide have shown significant activity in multiple myeloma. Combinations of these agents with steroids, alkylating agents or anthracyclines have significantly improved response rate and progression- free survival (PFS). In elderly patients, older than 65 years, oral melphalan and prednisone (MP) has been combined with thalidomide or bortezomib significantly improving response rate and PFS.

Supporting Agencies


Palumbo, A., Genuardi, M., & Bringhen, S. (2009). New treatment options for elderly myeloma patients: the Italian experience. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.557
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC